FDA revisits earlier proposal to add prescribing information to device labelling
This article was originally published in Clinica
Executive Summary
The FDA has decided to look again at medical device labelling. Two years ago the US agency put out a guidance recommending that companies add a brief abstract of key prescribing information in the labelling. The abstract, known as essential prescribing information, was intended to give practitioners a quick overview of the contents to be found in the full labelling.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.